Encyclopedia

  • Depletion of intracellular glutathione by 1-methyl-2-nitrosoimidazole (cas 116169-87-0)
  • Add time:07/21/2019         Source:sciencedirect.com

    In addition to their ability to radiosensitize, nitroimidazoles are selectively toxic toward hypoxic cells. Reduction of the nitro group is required to observe cytotoxicity. One of the reduction products believed to play a role in this cytotoxicity is the nitroso-derivative. One-methyl-2-nitrosoimidazole (INO), chemically synthesized from one-methyl-2-nitroimidazole (INO2), has been used as a model to study the reactivity of 2-nitrosoimidazoles. The ability of INO to react rapidly with glutathione in Chinese hamster ovary cells treated with a sub-toxic and toxic level of the drug has been measured. The kinetics of GSH loss as well as oxidized GSH (GSSG) formation and loss were assessed at short times (0–15 min) after INO exposure using a high pressure liquid chromatography (HPLC) assay for GSH and GSSG. The results obtained were consistent with a model, based on previous chemical studies of the reaction of INO with GSH, whereby GSH reduces INO forming GSSG and as well reacts with a reduced form of INO to form an adduct (I-SG). These results suggest possible strategies for modifying the toxicity of reduction products of one-substituted-2-nitroimidazoles.

    We also recommend Trading Suppliers and Manufacturers of 1-methyl-2-nitrosoimidazole (cas 116169-87-0). Pls Click Website Link as below: cas 116169-87-0 suppliers


    Prev:1-methyl-2-nitrosoimidazole (cas 116169-87-0): Cytotoxic and glutathione depleting capabilities
    Next: DNA damage induced in HT-29 colon cancer cells by exposure to 1-methyl-2-nitrosoimidazole (cas 116169-87-0), a reductive metabolite of 1-methyl-2-nitroimidazole)

About|Contact|Cas|Product Name|Molecular|Country|Encyclopedia

Message|New Cas|MSDS|Service|Advertisement|CAS DataBase|Article Data|Manufacturers | Chemical Catalog

©2008 LookChem.com,License: ICP

NO.:Zhejiang16009103

complaints:service@lookchem.com Desktop View